Skip to content
Review Open access

Therapeutic Potential of Oxiracetam in Neurocognitive Disorders: A Narrative Review

Aug 2026 · Brain and Behavior · Vol 16 · 0 citations · 44 references
Medicine

TL;DR

This review aims to evaluate the mechanistic basis, clinical efficacy, and safety profile of oxiracetam as a potential therapeutic agent for cognitive dysfunction across a range of neurological disorders.

Abstract

Purpose: Cognitive impairment is a growing global health concern associated with aging, neurodegenerative diseases, stroke, and traumatic brain injury. Existing pharmacological treatments, including cholinesterase inhibitors and memantine, provide limited and variable benefits. This review aims to evaluate the mechanistic basis, clinical efficacy, and safety profile of oxiracetam as a potential therapeutic agent for cognitive dysfunction across a range of neurological disorders.

Read PDF

Similar papers

Review Open access Aug 2026

The Apathy Syndrome Across Brain Disorders: Diagnosis, Neurobiological Mechanisms, and Therapeutic Strategies: A Narrative Review

Apathy is a common, disabling, and frequently under-recognised neuropsychiatric syndrome characterised by a quantitative reduction in goal-directed behaviour, cognition, and emotional engagement. It occurs across a broad range of neurological and psychiatric disorders, yet is routinely conflated with depression, cognit...

Vaidya Bala · 0 citations
Review Sep 2026

[Current perspectives on non-pharmacological approaches to cognitive impairment].

Cognitive impairment (CI) is increasingly recognized as a significant public health issue. Despite extensive research into its causes, mechanisms, and risk factors, along with advancements in pharmacological treatments for associated conditions, preventing or slowing the progression of cognitive decline often cannot be...

E. A. Gileva, E. A. Kovalenko, E. V. Makhnovich et al. · 0 citations
Open access Aug 2026

Efficacy and Safety of Electroconvulsive Therapy for Dementia With Lewy Bodies, Its Prodromal Phase, and Parkinson's Disease Dementia: Eight Cases Encountered at Our Institution

This study aimed to assess the efficacy and safety of electroconvulsive therapy (ECT) for treating psychiatric symptoms and parkinsonism in patients affected by dementia with Lewy bodies (DLB), its prodromal phase, and Parkinson's disease dementia (PDD).

Takahide Fukatsu, Kohei Fujita, Taro Yoshida et al. · 0 citations
Review 2026

Mechanism and Research Progress of Anti-Inflammatory Dietary Intervention in Tic Disorders and Their Comorbidities

: Tic disorder represents a prevalent neurodevelopmental disorder, yet conventional pharmacotherapy frequently causes notable adverse effects. Anti ‑ inflammatory diets show therapeutic promise for neuropsychiatric conditions through modulating gut microbiota and relieving neuro inflammation and oxidative stress. This...

Miao-Miao Gao, Qian Niu, Rui Jing · 0 citations
Review Aug 2026

[The biological role of neuroinflammation in the pathogenesis of mental disorders associated with pulmonary hypertension].

The article presents a narrative review of the recent scientific literature regarding mental disorders in patients diagnosed with pulmonary hypertension (PH). Psychosomatic disorders were considered, first of all, anxiety, depressive, potentially related to the systemic immune-inflammatory process of the underlying dis...

M. A. Samushiya, T. Klyushnik, D. Zateyshchikov et al. · 0 citations
Review Open access Sep 2026

Advances in the management of depression in Parkinson's disease: A narrative review on vortioxetine, hyperbaric oxygen, and physical activity.

Depression is one of the most prevalent and disabling non-motor symptoms of Parkinson's disease (PD), yet current treatments remain suboptimal, with many patients experiencing incomplete response to standard antidepressants. Growing evidence highlights the need for multimodal approaches addressing the complex neurobiol...

Irene Mesquita, B. Araújo, C. Soares-Guedes et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.